Share the post "Mankind Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 14.99 %, QoQ Down 8.73 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 14.99 % in the past year, decrease in net sales/revenue by -8.73 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 97.48 %. Marginal increase in other income during this quarter, up by 24.72%.
- Profit over the Year and quarter: Significant improvement in profitability for Mankind Pharma Limited. Notable increase of 61.63 % in net profit Year to Year, Mankind Pharma Limited’s profitability dropped by -6.76 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 61.77 % Year to Year. EPS decreased by -6.74 % in previous quarter. Analysis needed for shareholder value.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 1872.122 Cr | Rs. 2358.566 Cr | Rs. 2152.687 Cr | -8.73 % | + 14.99 % |
Expenses | Rs. 1490.96 Cr | Rs. 1755.46 Cr | Rs. 1605.35 Cr | -8.55 % | + 7.67 % |
Operating Profit | Rs. 381.16 Cr | Rs. 603.11 Cr | Rs. 547.34 Cr | -9.25 % | + 43.6 % |
OPM % | 20.36 % | 25.57 % | 25.43 % | -0.14 % | + 5.07 % |
Other Income | Rs. 42.46 Cr | Rs. 67.23 Cr | Rs. 83.85 Cr | + 24.72 % | + 97.48 % |
Interest | Rs. 0.89 Cr | Rs. 4.26 Cr | Rs. 4.04 Cr | -5.16 % | + 353.93 % |
Depreciation | Rs. 67.3 Cr | Rs. 89.73 Cr | Rs. 82.29 Cr | -8.29 % | + 22.27 % |
Profit before tax | Rs. 355.43 Cr | Rs. 576.35 Cr | Rs. 544.86 Cr | -5.46 % | + 53.3 % |
Tax % | 20.95 % | 15.49 % | 16.64 % | + 1.15 % | -4.31 % |
Net Profit | Rs. 280.99 Cr | Rs. 487.07 Cr | Rs. 454.17 Cr | -6.75 % | + 61.63 % |
EPS in Rs | Rs. 7.01 | Rs. 12.16 | Rs. 11.34 | -6.74 % | + 61.77 % |
Today, we’re looking at Mankind Pharma Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 14.99 %. However, it did see a marginal slip of -8.73 % from the previous quarter. Expenses decreased slightly by -8.55 % quarter-on-quarter, aligning with the annual rise of 7.67 %. Operating profit, while up 43.6 % compared to last year, faced a quarter-on-quarter dip of -9.25 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 5.07 %, but a shrinkage of -0.14 % sequentially. Other income rose by 24.72 % compared to the last quarter, despite an annual growth of 97.48 %. Interest expenses dropped significantly by -5.16 % from the previous quarter, yet the year-over-year increase remains at a moderate 353.93 %. Depreciation costs fell by -8.29 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 22.27 %. Profit before tax grew annually by 53.3 % but saw a reduction from the preceding quarter by -5.46 %.
Tax expenses as a percentage of profits decreased slightly by -4.31 % compared to last year, with a more notable quarter-on-quarter increase of 1.15 %. Net profit rose by 61.63 % year-on-year but witnessed a -6.75 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 61.77 % but a quarterly fall of -6.74 %. In summary, Mankind Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 1872.122 Cr | Rs. 2358.566 Cr | Rs. 2152.687 Cr | -8.73 % | + 14.99 % |
Expenses | Rs. 1490.96 Cr | Rs. 1755.46 Cr | Rs. 1605.35 Cr | -8.55 % | + 7.67 % |
Operating Profit | Rs. 381.16 Cr | Rs. 603.11 Cr | Rs. 547.34 Cr | -9.25 % | + 43.6 % |
Net Profit | Rs. 280.99 Cr | Rs. 487.07 Cr | Rs. 454.17 Cr | -6.75 % | + 61.63 % |
EPS in Rs | Rs. 7.01 | Rs. 12.16 | Rs. 11.34 | -6.74 % | + 61.77 % |
In reviewing Mankind Pharma Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 14.99 % year-on-year growth, although there was a slight dip of -8.73 % from the previous quarter. Expenses rose by 7.67 % compared to the previous year, with a decrease of -8.55 % quarter-on-quarter. Operating Profit surged by 43.6 % annually, and saw a -9.25 % decrease from the last quarter.
Net Profit showed yearly increase of 61.63 %, and experienced a -6.75 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 61.77 % annually, however dipped by -6.74 % compared to the last quarter. In essence, while Mankind Pharma Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
18
3-Year Profit
27
5-Year Profit
0
10-Year Profit
2,690
Current Price
1,07,773
Market Cap
In analyzing the financial results for the company marked by BSE code 543904, a clear trend emerges. Over a five-year span, the company reported a profit of 27 percents, which increased to 18 percents in the most recent three-year period, suggesting a strong performance in the early stages of this timeframe. However, this success has been overshadowed by a trailing twelve-month (TTM) loss of 41 percents, signaling significant recent challenges. Compounding this issue is the fact that the company has not reported any sales during any of the timeframes analyzed, raising important questions about its operational model and the sustainability of its current strategies. Investors have been equally wary, as reflected in the stock price performance. The company’s stock traded at 0 percents over the past five years but has recently decreased to 40 percents, indicating a loss of market confidence. Over the last decade, the stock price was at 0 percents, pointing to longer-term concerns that could affect the company's future prospects.
With a market capitalization of ₹1,07,773 crore, the company’s stock is currently trading at ₹2,690, having fluctuated within a range of ₹2,786 / 1,683 over the years. The stock's P/E ratio of 54.9 reflects a relatively high valuation compared to its earnings, which could suggest strong future growth expectations or heightened investor demand. The company’s book value is ₹234, representing the total value of its assets on a per-share basis, while the dividend yield of 0.00% offers a modest return to shareholders. ROCE, at 26.2%, highlights the company's efficient use of capital in generating profits, while ROE at 21.5% underscores its ability to generate returns for shareholders. The debt-to-equity ratio of 0.02 is very low, indicating conservative financial management and minimal reliance on borrowed funds. Despite this, the company shows a negative net cash flow of ₹77.2 crore, which could point to cash management challenges or recent heavy investments. The Piotroski score of 9.00 suggests moderate financial strength, while the Graham Number, pegged at ₹508, offers a rough estimate of the stock's intrinsic value. The Price-to-Book (P/B) ratio of 11.5 signals that the stock is trading at a premium, which might reflect investor confidence in the company's growth trajectory.